Q2 2023 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2023-08-14 · accession 0001104659-23-091405
$5.30B
Reported value
54
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.00B | 18.9% | 11,225,357 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $432.5M | 8.16% | 6,264,707 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $394.1M | 7.44% | 7,891,254 | Common | SOLE |
| 23345J104 | — | DICE THERAPEUTICS INC | $365.0M | 6.89% | 7,856,612 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $216.4M | 4.08% | 11,416,948 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $151.8M | 2.87% | 532,892 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $141.7M | 2.68% | 8,263,982 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $133.6M | 2.52% | 6,317,990 | Common | SOLE |
| N2451R105 | CVAC | CUREVAC N V | $127.6M | 2.41% | 12,245,955 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $123.2M | 2.33% | 7,236,454 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $107.0M | 2.02% | 9,000,000 | Common | SOLE |
| 23285D109 | CTKB | CYTEK BIOSCIENCES INC | $105.0M | 1.98% | 12,297,721 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $102.9M | 1.94% | 8,670,644 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $101.3M | 1.91% | 31,544,806 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX INC | $100.0M | 1.89% | 3,853,867 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $93.6M | 1.77% | 5,676,067 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $93.2M | 1.76% | 7,809,852 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $87.9M | 1.66% | 3,052,796 | Common | SOLE |
| 19240Q201 | COGT | COGENT COMMUNICATIONS HLDGS | $76.0M | 1.43% | 6,416,147 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $72.7M | 1.37% | 8,131,952 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $71.9M | 1.36% | 1,000,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $71.2M | 1.34% | 6,416,998 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $70.3M | 1.33% | 22,748,880 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $66.3M | 1.25% | 5,587,333 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $62.6M | 1.18% | 17,202,009 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $62.3M | 1.18% | 4,810,508 | Common | SOLE |
| 45114M109 | — | ICOSAVAX INC | $59.2M | 1.12% | 5,963,565 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $58.5M | 1.10% | 4,417,259 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $55.5M | 1.05% | 3,069,531 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $54.2M | 1.02% | 3,178,476 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $48.2M | 0.91% | 4,691,178 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $47.8M | 0.90% | 2,007,946 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $47.0M | 0.89% | 9,770,773 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $45.6M | 0.86% | 4,398,453 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $44.0M | 0.83% | 2,329,958 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $43.3M | 0.82% | 2,122,465 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $38.3M | 0.72% | 11,609,704 | Common | SOLE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $36.8M | 0.70% | 13,150,849 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $35.6M | 0.67% | 6,067,483 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $32.1M | 0.61% | 3,773,517 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $31.9M | 0.60% | 1,762,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $29.3M | 0.55% | 3,370,506 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $20.2M | 0.38% | 3,009,678 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $18.7M | 0.35% | 6,144,881 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $18.7M | 0.35% | 2,971,231 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $18.0M | 0.34% | 3,426,286 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $17.8M | 0.34% | 3,525,754 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $17.1M | 0.32% | 7,805,129 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $15.4M | 0.29% | 1,400,001 | Common | SOLE |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $8.7M | 0.16% | 937,500 | Common | SOLE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $7.9M | 0.15% | 6,991,003 | Common | SOLE |
| 87410C104 | — | TALARIS THERAPEUTICS INC | $7.1M | 0.13% | 2,333,175 | Common | SOLE |
| 63009R109 | NSTGEUR | NANOSTRING TECHNOLOGIES | $7.0M | 0.13% | 1,723,373 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $696,666 | 0.01% | 333,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.